{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:32:28Z","timestamp":1790620348958,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01922-x","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:48:24Z","timestamp":1790066904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Functional antibody responses and protection against symptomatic dengue"],"prefix":"10.1038","volume":"6","author":[{"given":"Caroline Lin Lin","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Thi My","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-5006","authenticated-orcid":false,"given":"Carla Bianca Luena","family":"Victorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinit","family":"Upasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Ju Min","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4520-2701","authenticated-orcid":false,"given":"Andrew","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1473-3099(24)00158-0","volume":"24","author":"Core IHME Pathogen","year":"2024","unstructured":"IHME Pathogen, C. ore Group. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Infect. Dis. 24, 868\u2013895 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1922_CR2","unstructured":"World Health Organization. Disease Outbreak News; Dengue \u2013 Global situation. 2024 (WHO, 2024)."},{"key":"1922_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(23)02576-X","volume":"403","author":"G Paz-Bailey","year":"2024","unstructured":"Paz-Bailey, G., Adams, L. E., Deen, J., Anderson, K. B. & Katzelnick, L. C. Dengue. Lancet 403, 667\u2013682 (2024).","journal-title":"Lancet"},{"key":"1922_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011223","volume":"19","author":"A Teo","year":"2023","unstructured":"Teo, A., Tan, H. D., Loy, T., Chia, P. Y. & Chua, C. L. L. Understanding antibody-dependent enhancement in dengue: are afucosylated IgG1s a concern? PLoS Pathog. 19, e1011223 (2023).","journal-title":"PLoS Pathog."},{"key":"1922_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53916-9","volume":"16","author":"CD Odio","year":"2025","unstructured":"Odio, C. D. et al. Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective. Nat. Commun. 16, 191 (2025).","journal-title":"Nat. Commun."},{"key":"1922_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3151","volume":"14","author":"AG Dias Jr.","year":"2022","unstructured":"Dias, A. G. Jr. et al. Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. Sci. Transl. Med. 14, eabm3151 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1922_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/antib12020036","volume":"12","author":"Z Sampei","year":"2023","unstructured":"Sampei, Z. et al. Complement activation by an anti-dengue\/Zika antibody with impaired Fc\u03b3 receptor binding provides strong efficacy and abrogates risk of antibody-dependent enhancement. Antibodies 12, 36 (2023).","journal-title":"Antibodies"},{"key":"1922_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/infdis\/jiae137","volume":"230","author":"LA Sanchez-Vargas","year":"2024","unstructured":"Sanchez-Vargas, L. A. et al. Protective role of NS1-specific antibodies in the immune response to dengue virus through antibody-dependent cellular cytotoxicity. J. Infect. Dis. 230, 1147\u20131156 (2024).","journal-title":"J. Infect. Dis."},{"key":"1922_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108226","volume":"33","author":"DR Martinez","year":"2020","unstructured":"Martinez, D. R. et al. Antigenic variation of the dengue virus 2 genotypes impacts the neutralization activity of human antibodies in vaccinees. Cell Rep. 33, 108226 (2020).","journal-title":"Cell Rep."},{"key":"1922_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.mib.2008.06.004","volume":"11","author":"R Perera","year":"2008","unstructured":"Perera, R. & Kuhn, R. J. Structural proteomics of dengue virus. Curr. Opin. Microbiol. 11, 369\u2013377 (2008).","journal-title":"Curr. Opin. Microbiol."},{"key":"1922_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nsb990","volume":"10","author":"W Zhang","year":"2003","unstructured":"Zhang, W. et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10, 907\u2013912 (2003).","journal-title":"Nat. Struct. Biol."},{"key":"1922_CR12","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.1128\/JVI.00757-13","volume":"87","author":"G Fibriansah","year":"2013","unstructured":"Fibriansah, G. et al. Structural changes in dengue virus when exposed to a temperature of 37\u2009\u00b0C. J. Virol. 87, 7585\u20137592 (2013).","journal-title":"J. Virol."},{"key":"1922_CR13","doi-asserted-by":"publisher","first-page":"1004608","DOI":"10.3389\/fcimb.2022.1004608","volume":"12","author":"MF Lee","year":"2022","unstructured":"Lee, M. F., Voon, G. Z., Lim, H. X., Chua, M. L. & Poh, C. L. Innate and adaptive immune evasion by dengue virus. Front Cell Infect. Microbiol 12, 1004608 (2022).","journal-title":"Front Cell Infect. Microbiol"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/CVI.00081-16","volume":"23","author":"R Alves","year":"2016","unstructured":"Alves, R. et al. Production of a recombinant dengue virus 2 NS5 protein and potential use as a vaccine antigen. Clin. Vaccin. Immunol. 23, 460\u2013469 (2016).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1922_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44330-8","volume":"15","author":"S Bos","year":"2024","unstructured":"Bos, S. et al. Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype. Nat. Commun. 15, 382 (2024).","journal-title":"Nat. Commun."},{"key":"1922_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1073\/pnas.1522136113","volume":"113","author":"LC Katzelnick","year":"2016","unstructured":"Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc. Natl. Acad. Sci. USA. 113, 728\u2013733 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1922_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s43856-023-00378-7","volume":"3","author":"A Anantharaj","year":"2023","unstructured":"Anantharaj, A. et al. Neutralizing antibodies from prior exposure to dengue virus negatively correlate with viremia on re-infection. Commun. Med. 3, 148 (2023).","journal-title":"Commun. Med."},{"key":"1922_CR18","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","volume":"75","author":"WD Crill","year":"2001","unstructured":"Crill, W. D. & Roehrig, J. T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75, 7769\u20137773 (2001).","journal-title":"J. Virol."},{"key":"1922_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nsmb.1382","volume":"15","author":"SM Lok","year":"2008","unstructured":"Lok, S. M. et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15, 312\u2013317 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1922_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2015.06.057","volume":"162","author":"LN Robinson","year":"2015","unstructured":"Robinson, L. N. et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell 162, 493\u2013504 (2015).","journal-title":"Cell"},{"key":"1922_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","volume":"349","author":"G Fibriansah","year":"2015","unstructured":"Fibriansah, G. et al. Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349, 88\u201391 (2015).","journal-title":"Science"},{"key":"1922_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7341","volume":"6","author":"G Fibriansah","year":"2015","unstructured":"Fibriansah, G. et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun. 6, 6341 (2015).","journal-title":"Nat. Commun."},{"key":"1922_CR23","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1016\/j.vaccine.2006.01.036","volume":"24","author":"L Hermida","year":"2006","unstructured":"Hermida, L. et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24, 3165\u20133171 (2006).","journal-title":"Vaccine"},{"key":"1922_CR24","doi-asserted-by":"publisher","first-page":"e0003947","DOI":"10.1371\/journal.pntd.0003947","volume":"9","author":"M Poggianella","year":"2015","unstructured":"Poggianella, M. et al. Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes. PLoS Negl. Trop. Dis. 9, e0003947 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1922_CR25","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.ymthe.2022.01.013","volume":"30","author":"A Sankaradoss","year":"2022","unstructured":"Sankaradoss, A. et al. Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences. Mol. Ther. 30, 2058\u20132077 (2022).","journal-title":"Mol. Ther."},{"key":"1922_CR26","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.vaccine.2023.01.062","volume":"41","author":"M Seesen","year":"2023","unstructured":"Seesen, M. et al. A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells. Vaccine 41, 1638\u20131648 (2023).","journal-title":"Vaccine"},{"key":"1922_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1128\/JVI.01826-10","volume":"85","author":"CM Midgley","year":"2011","unstructured":"Midgley, C. M. et al. An in-depth analysis of original antigenic sin in dengue virus infection. J. Virol. 85, 410\u2013421 (2011).","journal-title":"J. Virol."},{"key":"1922_CR28","doi-asserted-by":"publisher","first-page":"1200195","DOI":"10.3389\/fimmu.2023.1200195","volume":"14","author":"A Sarker","year":"2023","unstructured":"Sarker, A., Dhama, N. & Gupta, R. D. Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement. Front Immunol. 14, 1200195 (2023).","journal-title":"Front Immunol."},{"key":"1922_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","volume":"392","author":"WM Wahala","year":"2009","unstructured":"Wahala, W. M., Kraus, A. A., Haymore, L. B., Accavitti-Loper, M. A. & de Silva, A. M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392, 103\u2013113 (2009).","journal-title":"Virology"},{"key":"1922_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virol.2012.03.003","volume":"429","author":"KL Williams","year":"2012","unstructured":"Williams, K. L., Wahala, W. M., Orozco, S., de Silva, A. M. & Harris, E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429, 12\u201320 (2012).","journal-title":"Virology"},{"key":"1922_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq0571","volume":"17","author":"PI Mpingabo","year":"2025","unstructured":"Mpingabo, P. I. et al. Protective envelope dimer epitope-like antibodies are elicited against dengue virus in children after infection and vaccination. Sci. Transl. Med. 17, eadq0571 (2025).","journal-title":"Sci. Transl. Med"},{"key":"1922_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","volume":"16","author":"W Dejnirattisai","year":"2015","unstructured":"Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170\u2013177 (2015).","journal-title":"Nat. Immunol."},{"key":"1922_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109\u2013113 (2015).","journal-title":"Nature"},{"key":"1922_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/infdis\/jiu481","volume":"211","author":"KS Corbett","year":"2015","unstructured":"Corbett, K. S. et al. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J. Infect. Dis. 211, 590\u2013599 (2015).","journal-title":"J. Infect. Dis."},{"key":"1922_CR35","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1128\/JCM.43.6.2793-2797.2005","volume":"43","author":"S Matheus","year":"2005","unstructured":"Matheus, S. et al. Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. J. Clin. Microbiol. 43, 2793\u20132797 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"1922_CR36","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1093\/infdis\/jiaf171","volume":"232","author":"I Tsuji","year":"2025","unstructured":"Tsuji, I. et al. Anti-dengue virus antibody avidity correlates with protection against symptomatic dengue virus infection. J. Infect. Dis. 232, e99\u2013e103 (2025).","journal-title":"J. Infect. Dis."},{"key":"1922_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jcv.2015.06.003","volume":"69","author":"L Lau","year":"2015","unstructured":"Lau, L., Green, A. M., Balmaseda, A. & Harris, E. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity. J. Clin. Virol. 69, 63\u201367 (2015).","journal-title":"J. Clin. Virol."},{"key":"1922_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1086\/512860","volume":"195","author":"K Laoprasopwattana","year":"2007","unstructured":"Laoprasopwattana, K. et al. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J. Infect. Dis. 195, 1108\u20131116 (2007).","journal-title":"J. Infect. Dis."},{"key":"1922_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jim.2016.11.005","volume":"441","author":"P Sun","year":"2017","unstructured":"Sun, P. et al. NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients. J. Immunol. Methods 441, 24\u201330 (2017).","journal-title":"J. Immunol. Methods"},{"key":"1922_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36972-2","volume":"9","author":"P Sun","year":"2019","unstructured":"Sun, P. et al. NK cells activated through antibody-dependent cell cytotoxicity and armed with degranulation\/IFN-\u03b3 production suppress antibody-dependent enhancement of dengue viral infection. Sci. Rep. 9, 1109 (2019).","journal-title":"Sci. Rep."},{"key":"1922_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae720","volume":"12","author":"MJ Waldran","year":"2025","unstructured":"Waldran, M. J. et al. Dengue virus structural proteins are expressed on the surface of denv-infected cells and are a target for antibody-dependent cellular phagocytosis. Open Forum Infect. Dis. 12, ofae720 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"1922_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/infdis\/jiad122","volume":"228","author":"MJ Waldran","year":"2023","unstructured":"Waldran, M. J. et al. Soluble NS1 antagonises IgG- and IgA- mediated monocytic phagocytosis of DENV-infected cells. J. Infect. Dis. 228, 70\u201379 (2023).","journal-title":"J. Infect. Dis."},{"key":"1922_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104384","volume":"25","author":"D Maheshwari","year":"2022","unstructured":"Maheshwari, D. et al. Contrasting behaviour between the three human monocyte subsets in dengue pathophysiology. iScience 25, 104384 (2022).","journal-title":"iScience"},{"key":"1922_CR44","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/infdis\/jiac476","volume":"227","author":"EJM Nascimento","year":"2023","unstructured":"Nascimento, E. J. M. et al. Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system. J. Infect. Dis. 227, 1282\u20131292 (2023).","journal-title":"J. Infect. Dis."},{"key":"1922_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115613","volume":"44","author":"AG Dias Jr.","year":"2025","unstructured":"Dias, A. G. Jr. et al. Anti-dengue virus antibodies that elicit complement-mediated lysis of Zika virion correlate with protection from severe dengue disease. Cell Rep. 44, 115613 (2025).","journal-title":"Cell Rep."},{"key":"1922_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100278","volume":"2","author":"A Rouers","year":"2021","unstructured":"Rouers, A. et al. Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection. Cell Rep. Med. 2, 100278 (2021).","journal-title":"Cell Rep. Med."},{"key":"1922_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.777672","volume":"12","author":"AD Wegman","year":"2021","unstructured":"Wegman, A. D. et al. Monomeric IgA antagonizes IgG-mediated enhancement of DENV infection. Front Immunol. 12, 777672 (2021).","journal-title":"Front Immunol."},{"key":"1922_CR48","doi-asserted-by":"publisher","first-page":"e1011616","DOI":"10.1371\/journal.ppat.1011616","volume":"19","author":"AD Wegman","year":"2023","unstructured":"Wegman, A. D. et al. DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog. 19, e1011616 (2023).","journal-title":"PLoS Pathog."},{"key":"1922_CR49","doi-asserted-by":"publisher","first-page":"e1010065","DOI":"10.1371\/journal.ppat.1010065","volume":"17","author":"A Teo","year":"2021","unstructured":"Teo, A., Chua, C. L. L., Chia, P. Y. & Yeo, T. W. Insights into potential causes of vascular hyperpermeability in dengue. PLoS Pathog. 17, e1010065 (2021).","journal-title":"PLoS Pathog."},{"key":"1922_CR50","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41590-025-02363-9","volume":"27","author":"JA Cardona-Ospina","year":"2026","unstructured":"Cardona-Ospina, J. A. et al. IgA-driven neutrophil activation underlies severe dengue disease after primary Zika virus infection in humans. Nat. Immunol. 27, 126\u2013134 (2026).","journal-title":"Nat. Immunol."},{"key":"1922_CR51","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.tim.2024.04.011","volume":"32","author":"CLL Chua","year":"2024","unstructured":"Chua, C. L. L., Morales, R. F., Chia, P. Y., Yeo, T. W. & Teo, A. Neutrophils - an understudied bystander in dengue? Trends Microbiol 32, 1132\u20131142 (2024).","journal-title":"Trends Microbiol"},{"key":"1922_CR52","doi-asserted-by":"publisher","first-page":"e1074","DOI":"10.1093\/cid\/ciaa1840","volume":"72","author":"NL Vuong","year":"2021","unstructured":"Vuong, N. L. et al. Higher plasma viremia in the febrile phase is associated with adverse dengue outcomes irrespective of infecting serotype or host immune status: an analysis of 5642 Vietnamese cases. Clin. Infect. Dis. 72, e1074\u2013e1083 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1922_CR53","doi-asserted-by":"publisher","first-page":"RP92606","DOI":"10.7554\/eLife.92606","volume":"13","author":"NL Vuong","year":"2024","unstructured":"Vuong, N. L. et al. Dengue viremia kinetics and effects on platelet count and clinical outcomes: an analysis of 2340 patients from Vietnam. Elife 13, RP92606 (2024).","journal-title":"Elife"},{"key":"1922_CR54","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41564-023-01421-y","volume":"8","author":"R Yamin","year":"2023","unstructured":"Yamin, R. et al. Human Fc\u03b3RIIIa activation on splenic macrophages drives dengue pathogenesis in mice. Nat. Microbiol. 8, 1468\u20131479 (2023).","journal-title":"Nat. Microbiol."},{"key":"1922_CR55","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41591-024-02798-x","volume":"30","author":"C Aggarwal","year":"2024","unstructured":"Aggarwal, C. et al. Severe disease during both primary and secondary dengue virus infections in pediatric populations. Nat. Med. 30, 670\u2013674 (2024).","journal-title":"Nat. Med"},{"key":"1922_CR56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4269\/ajtmh.24-0508","volume":"113","author":"D Camprub\u00ed-Ferrer","year":"2025","unstructured":"Camprub\u00ed-Ferrer, D. et al. Severity of primary and secondary dengue virus 1 infections: a hospital-based study in Puerto Rico, 2012-2014. Am. J. Trop. Med. Hyg. 113, 361\u2013365 (2025).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1922_CR57","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1128\/JVI.06335-11","volume":"86","author":"SA Smith","year":"2012","unstructured":"Smith, S. A. et al. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J. Virol. 86, 2665\u20132675 (2012).","journal-title":"J. Virol."},{"key":"1922_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","volume":"557","author":"H Salje","year":"2018","unstructured":"Salje, H. et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557, 719\u2013723 (2018).","journal-title":"Nature"},{"key":"1922_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745\u2013748 (2010).","journal-title":"Science"},{"key":"1922_CR60","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1086\/519170","volume":"196","author":"CP Simmons","year":"2007","unstructured":"Simmons, C. P. et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196, 416\u2013424 (2007).","journal-title":"J. Infect. Dis."},{"key":"1922_CR61","doi-asserted-by":"publisher","first-page":"11800","DOI":"10.1128\/JVI.05237-11","volume":"85","author":"IA Rodenhuis-Zybert","year":"2011","unstructured":"Rodenhuis-Zybert, I. A. et al. A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J. Virol. 85, 11800\u201311808 (2011).","journal-title":"J. Virol."},{"key":"1922_CR62","doi-asserted-by":"publisher","first-page":"e1004386","DOI":"10.1371\/journal.ppat.1004386","volume":"10","author":"R de Alwis","year":"2014","unstructured":"de Alwis, R. et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 10, e1004386 (2014).","journal-title":"PLoS Pathog."},{"key":"1922_CR63","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1126\/science.abc7303","volume":"372","author":"S Bournazos","year":"2021","unstructured":"Bournazos, S. et al. Antibody fucosylation predicts disease severity in secondary dengue infection. Science 372, 1102\u20131105 (2021).","journal-title":"Science"},{"key":"1922_CR64","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.aai8128","volume":"355","author":"TT Wang","year":"2017","unstructured":"Wang, T. T. et al. IgG antibodies to dengue enhanced for Fc\u03b3RIIIA binding determine disease severity. Science 355, 395\u2013398 (2017).","journal-title":"Science"},{"key":"1922_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx7231","volume":"17","author":"U Ashraf","year":"2025","unstructured":"Ashraf, U. et al. Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination. Sci. Transl. Med. 17, eadx7231 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1922_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107642","volume":"31","author":"NK Thulin","year":"2020","unstructured":"Thulin, N. K. et al. Maternal anti-dengue IgG fucosylation predicts susceptibility to dengue disease in infants. Cell Rep. 31, 107642 (2020).","journal-title":"Cell Rep."},{"key":"1922_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38453-1","volume":"14","author":"A Gupta","year":"2023","unstructured":"Gupta, A. et al. Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody. Nat. Commun. 14, 2853 (2023).","journal-title":"Nat. Commun."},{"key":"1922_CR68","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/cid\/ciad637","volume":"78","author":"A Teo","year":"2024","unstructured":"Teo, A., Le, C. T. T., Tan, T., Chia, P. Y. & Yeo, T. W. Febrile phase soluble urokinase plasminogen activator receptor and olfactomedin 4 as prognostic biomarkers for severe dengue in adults. Clin. Infect. Dis. 78, 788\u2013796 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1922_CR69","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.4049\/jimmunol.1102218","volume":"187","author":"YC Chuang","year":"2011","unstructured":"Chuang, Y. C. et al. Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation. J. Immunol. 187, 6483\u20136490 (2011).","journal-title":"J. Immunol."},{"key":"1922_CR70","doi-asserted-by":"publisher","first-page":"13759","DOI":"10.1128\/JVI.02166-14","volume":"88","author":"YC Chuang","year":"2014","unstructured":"Chuang, Y. C., Lin, Y. S., Liu, H. S. & Yeh, T. M. Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis. J. Virol. 88, 13759\u201313768 (2014).","journal-title":"J. Virol."},{"key":"1922_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/1096-9071(200103)63:3<247::AID-JMV1008>3.0.CO;2-F","volume":"63","author":"YH Huang","year":"2001","unstructured":"Huang, Y. H. et al. Activation of coagulation and fibrinolysis during dengue virus infection. J. Med. Virol. 63, 247\u2013251 (2001).","journal-title":"J. Med. Virol."},{"key":"1922_CR72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/jmv.10261","volume":"69","author":"CF Lin","year":"2003","unstructured":"Lin, C. F. et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J. Med. Virol. 69, 82\u201390 (2003).","journal-title":"J. Med. Virol."},{"key":"1922_CR73","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1160\/th15-06-0498","volume":"115","author":"SW Wan","year":"2016","unstructured":"Wan, S. W. et al. Anti-dengue virus nonstructural protein 1 antibodies contribute to platelet phagocytosis by macrophages. Thromb. Haemost. 115, 646\u2013656 (2016).","journal-title":"Thromb. Haemost."},{"key":"1922_CR74","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1086\/500949","volume":"193","author":"P Avirutnan","year":"2006","unstructured":"Avirutnan, P. et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193, 1078\u20131088 (2006).","journal-title":"J. Infect. Dis."},{"key":"1922_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07667-z","volume":"9","author":"D Jayathilaka","year":"2018","unstructured":"Jayathilaka, D. et al. Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection. Nat. Commun. 9, 5242 (2018).","journal-title":"Nat. Commun."},{"key":"1922_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf529","volume":"12","author":"S Noisakran","year":"2025","unstructured":"Noisakran, S. et al. Anti-nonstructural protein 1 antibody kinetics and their association with disease severity in pediatric dengue. Open Forum Infect. Dis. 12, ofaf529 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"1922_CR77","doi-asserted-by":"crossref","unstructured":"Premazzi Papa, M. et al. Dengue NS1 antibodies are associated with clearance of viral NS1. J Infect Dis. 230, 1226\u20131234 (2024).","DOI":"10.1093\/infdis\/jiae299"},{"key":"1922_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91099-5","volume":"15","author":"DA Muller","year":"2025","unstructured":"Muller, D. A. et al. Kinetics of NS1 and anti-NS1 IgG following dengue infection reveals likely early formation of immune complexes in secondary infected patients. Sci. Rep. 15, 6684 (2025).","journal-title":"Sci. Rep."},{"key":"1922_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07308-3","volume":"7","author":"YC Lai","year":"2017","unstructured":"Lai, Y. C. et al. Antibodies against modified NS1 wing domain peptide protect against dengue virus infection. Sci. Rep. 7, 6975 (2017).","journal-title":"Sci. Rep."},{"key":"1922_CR80","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1126\/science.abc0476","volume":"371","author":"SB Biering","year":"2021","unstructured":"Biering, S. B. et al. Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction. Science 371, 194\u2013200 (2021).","journal-title":"Science"},{"key":"1922_CR81","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/v13081446","volume":"13","author":"G Fibriansah","year":"2021","unstructured":"Fibriansah, G., Lim, X. N. & Lok, S. M. Morphological diversity and dynamics of dengue virus affecting antigenicity. Viruses 13, 1446 (2021).","journal-title":"Viruses"},{"key":"1922_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686691","volume":"12","author":"F Falconi-Agapito","year":"2021","unstructured":"Falconi-Agapito, F. et al. Dynamics of the magnitude, breadth and depth of the antibody response at epitope level following dengue infection. Front Immunol. 12, 686691 (2021).","journal-title":"Front Immunol."},{"key":"1922_CR83","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12985-024-02459-y","volume":"21","author":"VSL Goh","year":"2024","unstructured":"Goh, V. S. L. et al. Evaluation of three alternative methods to the plaque reduction neutralizing assay for measuring neutralizing antibodies to dengue virus serotype 2. Virol. J. 21, 208 (2024).","journal-title":"Virol. J."},{"key":"1922_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00918-23","volume":"11","author":"P Keelapang","year":"2023","unstructured":"Keelapang, P. et al. Blockade-of-binding activities toward envelope-associated, type-specific epitopes as a correlative marker for dengue virus-neutralizing antibody. Microbiol. Spectr. 11, e0091823 (2023).","journal-title":"Microbiol. Spectr."},{"key":"1922_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817905","volume":"13","author":"HTM Vo","year":"2022","unstructured":"Vo, H. T. M. et al. Robust and functional immune memory up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort. Front. Immunol. 13, 817905 (2022).","journal-title":"Front. Immunol."},{"key":"1922_CR86","first-page":"351","volume":"215","author":"S Henein","year":"2017","unstructured":"Henein, S. et al. Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. J. Infect. Dis. 215, 351\u2013358 (2017).","journal-title":"J. Infect. Dis."},{"key":"1922_CR87","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","volume":"395","author":"V Tricou","year":"2020","unstructured":"Tricou, V. et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet 395, 1434\u20131443 (2020).","journal-title":"Lancet"},{"key":"1922_CR88","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/infdis\/jiac272","volume":"226","author":"CR DeMaso","year":"2022","unstructured":"DeMaso, C. R. et al. Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine. J. Infect. Dis. 226, 1959\u20131963 (2022).","journal-title":"J. Infect. Dis."},{"key":"1922_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00967-0","volume":"9","author":"S Mandaric","year":"2024","unstructured":"Mandaric, S. et al. Long term T cell response and safety of a tetravalent dengue vaccine in healthy children. npj Vaccines 9, 192 (2024).","journal-title":"npj Vaccines"},{"key":"1922_CR90","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/infdis\/jiz081","volume":"221","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 221, 867\u2013877 (2020).","journal-title":"J. Infect. Dis."},{"key":"1922_CR91","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/infdis\/jiab064","volume":"225","author":"I Tsuji","year":"2022","unstructured":"Tsuji, I., Dominguez, D., Egan, M. A. & Dean, H. J. Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine. J. Infect. Dis. 225, 1533\u20131544 (2022).","journal-title":"J. Infect. Dis."},{"key":"1922_CR92","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","volume":"390","author":"EG Kall\u00e1s","year":"2024","unstructured":"Kall\u00e1s, E. G. et al. Live, attenuated, tetravalent butantan-dengue vaccine in children and adults. N. Engl. J. Med. 390, 397\u2013408 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1922_CR93","doi-asserted-by":"publisher","first-page":"ciag349","DOI":"10.1093\/cid\/ciag349","volume":"1","author":"D Alexanderian","year":"2026","unstructured":"Alexanderian, D. et al. Safety and immunogenicity of the live-attenuated quadrivalent dengue vaccine V181 compared with Butantan-DV among healthy adults in Brazil: a randomized, double-blind, phase 2 trial. Clin. Infect. Dis. 1, ciag349 (2026).","journal-title":"Clin. Infect. Dis."},{"key":"1922_CR94","doi-asserted-by":"publisher","first-page":"e1003931","DOI":"10.1371\/journal.ppat.1003931","volume":"10","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention. PLoS Pathog. 10, e1003931 (2014).","journal-title":"PLoS Pathog."},{"key":"1922_CR95","doi-asserted-by":"publisher","first-page":"e0007142","DOI":"10.1371\/journal.pntd.0007142","volume":"13","author":"T Tuan Vu","year":"2019","unstructured":"Tuan Vu, T. et al. Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies. PLoS Negl. Trop. Dis. 13, e0007142 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1922_CR96","doi-asserted-by":"publisher","first-page":"05291","DOI":"10.7554\/eLife.05291","volume":"4","author":"A Syenina","year":"2015","unstructured":"Syenina, A., Jagaraj, C. J., Aman, S. A., Sridharan, A. & St John, A. L. Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fc\u03b3 receptors. Elife 4, 05291 (2015).","journal-title":"Elife"},{"key":"1922_CR97","doi-asserted-by":"publisher","first-page":"10128","DOI":"10.1128\/JVI.00792-06","volume":"80","author":"WW Rodrigo","year":"2006","unstructured":"Rodrigo, W. W., Jin, X., Blackley, S. D., Rose, R. C. & Schlesinger, J. J. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fc\u03b3RIIA (CD64) or Fc\u03b3RIIA (CD32). J. Virol. 80, 10128\u201310138 (2006).","journal-title":"J. Virol."},{"key":"1922_CR98","doi-asserted-by":"publisher","first-page":"12479","DOI":"10.1073\/pnas.1106568108","volume":"108","author":"KR Chan","year":"2011","unstructured":"Chan, K. R. et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc. Natl. Acad. Sci. USA. 108, 12479\u201312484 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01922-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:01:55Z","timestamp":1790110915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01922-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01922-x","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"494"}}